Safety and Tolerability of hRPC in Retinitis Pigmentosa
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
hRPC is a cell therapy for retinitis pigmentosa. This is a first-in-human, dose escalation
study in which participants with retinitis pigmentosa will receive a single subretinal
injection of hRPC cells in one eye to evaluate safety and tolerability.
Participants will be followed for two years to evaluate the safety and tolerability of hRPC
Additional testing will seek to establish any preliminary efficacy from hRPC.